What is cariprazine?

The treatment of bipolar disorder is complex due to the presence of varying configurations of symptoms in patients. The primary treatments for bipolar disorder are pharmacological, and often involve second generation antipsychotic drugs, such as cariprazine. Based on its high affinity for dopamine receptors, cariprazine has been proposed as a treatment for bipolar disorder.

What is the evidence for cariprazine as treatment for bipolar disorder?

Moderate quality evidence suggests medium-sized effects of greater improvement in acute mania symptoms with cariprazine than placebo or topiramate, although there was greater improvement with tamoxefin than with cariprazine. There was also less all-cause discontinuation with olanzapine than with cariprazine.

Moderate quality evidence suggests no differences in depression symptoms, response or remission between low (0.75-1.5 mg) and high (3 mg) dose cariprazine over 8 weeks.

Moderate to high quality evidence suggests cariprazine is associated with more akathisia, tremor, restlessness and weight gain than placebo (all small to medium-sized effects).

July 2020

Last updated at: 1:18 am, 7th July 2020
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.